Panama7/iStock Editorial via Getty Images Sanofi ( NASDAQ: SNY ) said the FDA has accepted for priority review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib, lenalidomide and dexamethasone for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma. Multiple myeloma is a type of blood cancer that develops in the plasma cells. The target action date for the FDA decision is September 27, 2024, the firm said.
The company added, a regulatory submission was also under review in the European Union. More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M.
